Subtype
Early Stage Breast Carcinoma
CI-CAN-00002563Explore in graph →
57 active trials2 approved drugs
- NCIt
- C94774
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002563Explore in graph →
Clinical trials
145 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (13)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07832279 | 1-Week Versus 3-Week PBI | recruiting | N/A | 818 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05906407 |
| COGNITION: Genomics-Guided Precision Oncology in Early High-Risk Breast Cancer(COGNITION) |
| recruiting |
| — |
| 2,000 |
| German Cancer Research CenterOTHER |
| 1 |
| Sep 15, 2026 |
| clinicaltrials |
| NCT07796880 | Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer | recruiting | Phase 2 | 80 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07215364 | Impact of Exercise on Quality of Life of EBC Patients on Treatment With Adjuvant AI With or Without CDK4/6 Inhibitors(EX-AI) | recruiting | N/A | 74 | Spanish Breast Cancer Research GroupOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05386719 | Cardiometabolic Screening Program | recruiting | N/A | 450 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06902311 | Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)(H-ASSIST) | recruiting | Phase 2 | 90 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07211178 | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies(GEMINI Breast) | recruiting | — | 900 | Tempus AIINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04458532 | Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer | recruiting | N/A | 152 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06536881 | Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming(GAMMER) | recruiting | N/A | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05812807 | Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | recruiting | Phase 3 | 1,295 | Alliance for Clinical Trials in OncologyOTHER | 3 | Aug 5, 2026 | clinicaltrials |
| NCT07017673 | Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | recruiting | Phase 2 | 34 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT04360330 | SABER Study for Selected Early Stage Breast Cancer(SABER) | recruiting | N/A | 18 | University of MiamiOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors(PROFFi) | recruiting | Phase 2 | 164 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07723209 | Radiation After No Axillary Nodal Sampling(RADIANS) | recruiting | N/A | 105 | NYU Langone HealthOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06970912 | ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer(DNADalHR) | recruiting | Phase 2 | 393 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07366112 | CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment(DNACDKHR) | recruiting | Phase 2 | 158 | Peking University People's HospitalOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05753618 | Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy(REaCT-OGF) | recruiting | Phase 4 | 242 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04891068 | BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer(BRE-04) | recruiting | Phase 2 | 40 | University of Illinois at ChicagoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05582499 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy(FASCINATE-N) | recruiting | Phase 2 | 716 | Fudan UniversityOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer(I-SPY) | recruiting | Phase 2 | 5,000 | QuantumLeap Healthcare CollaborativeOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07386444 | Inspiratory Muscle Training for Breast Cancer Patients on Chemotherapy(IMACT) | recruiting | N/A | 58 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05417867 | Evaluating the Association Among Changes in Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer | recruiting | — | 70 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06446882 | Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer(DEFINITIVE) | recruiting | N/A | 304 | Fundacio Clinic BarcelonaOTHER | 5 | Feb 20, 2026 | clinicaltrials |
| NCT07071038 | Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients(SWIVEL) | recruiting | Phase 2 | 62 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06324240 | Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT05559164 | Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted | recruiting | Phase 2 | 60 | Rutgers, The State University of New JerseyOTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | recruiting | Phase 2 | 88 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05929768 | Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | recruiting | Phase 3 | 2,400 | SWOG Cancer Research NetworkNETWORK | 3 | Nov 5, 2025 | clinicaltrials |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab | recruiting | Phase 3 | 300 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05957068 | Breast Cancer Exercise Intervention Study(BREXINT) | recruiting | N/A | 2,156 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05332561 | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | recruiting | Phase 2 | 240 | German Cancer Research CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04671511 | Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer(TADEN) | recruiting | N/A | 98 | Jewish General HospitalOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT04603209 | Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer | recruiting | — | 1,000 | Saint John's Cancer InstituteOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06035016 | Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer | recruiting | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05345860 | Adopting the MRD Strategy to Optimize Post-operation Adjuvant Therapies for Early Stage Breast Cancer(AMENDER) | recruiting | N/A | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Apr 26, 2022 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials